Table 1.
Target Cell | LMW-HA (kDa) | Receptor | Pathways | Inflammatory Effector | References |
---|---|---|---|---|---|
Neutrophils | |||||
100–200 | Not determined | Not determined | NE | [76,77] | |
200 | Not determined | PI3K/Akt1 | IL-6 | [78] | |
200 | Not determined | PI3K/Akt1 | KC | [78] | |
200 | Not determined | PI3K/Akt1 | MMP-9 | [78] | |
200 | Not determined | PI3K/Akt1 | MPO | [78] | |
200 | Not determined | PI3K/Akt1 | Mcl-1 | [78] | |
Macrophages | |||||
200 | TLR2 | NF-κB | MIP-1α/β | [60,79] | |
80 | TLR2 and TLR4 | Not determined | IL-8 | [74,80] | |
100–150 | TLR2 and TLR4 | NF-κB | CXCL2 | [80] | |
5 | TLR2 and TLR4 | Not determined | TNF-α | [81,82] | |
5–200 | Not determined | NF-κB | NO | [81] | |
Not determined | TLR2 and TLR4 | Not determined | IL-1β | [81] | |
60-200 | Not determined | NF-κB | MMP-9 | [82] | |
Not determined | Not determined | Not determined | PAI-1 | [83] | |
Not determined | Not determined | Not determined | uPA | [83] | |
80 | TLR4 | NF-κB | IFN-β | [84] | |
100–150 | CD44-TLR4 | Not determined | IL-6 | [85] | |
100–150 | CD44-TLR4 | ERK1/2 and p38MAPK | MCP-1 | [85] | |
200 | TLR4 | IRF3 | IFN-β | [86] | |
200 | cPLA2α Phosphorylation | ERK1/2, p38MAPK and JNK | COX2 | [87] | |
200 | cPLA2α Phosphorylation | ERK1/2, p38MAPK and JNK | PGE2 | [87] | |
200 | Not determined | NF-κB | iNOS | [88] | |
200 | Not determined | Not determined | MMP-12 | [89] | |
280 | CD44 | Not determined | IL-12 | [90] | |
Dendritic Cells | |||||
80–200 | TLR4 | Not determined | IL-12 | [91,92] | |
80–200 | TLR4 | Not determined | TNF-α | [91,92] | |
80–200 | TLR4 | Not determined | IL-1β | [91,92] | |
Lung Epithelial Cells | |||||
Not determined | TLR4 | Not determined | IL-6 | [61] | |
Not determined | CD44/TLR4/MD2/ MyD88 | NF-κB | MIP-2 | [61] | |
Not determined | CD44/TLR4/MD2/ Ras | NF-κB | MMP-13 | [61] | |
Not determined | CD44/TLR4/MD2/ Ras | NF-κB | TGF-β2 | [61] | |
200 | Not determined | ERK1/2, AP-1, NF-κB and JNK | IL-8 | [93,94] | |
200 | Not determined | NF-κB | IP-10 | [93] |